 Home > Biochemistry News > Biotechnology News > Over 1.7 billion U.S. dollars to help develop ophthalmic gene therapy AbbVie reached cooperation

Over 1.7 billion U.S. dollars to help develop ophthalmic gene therapy AbbVie reached cooperation

 Last Update: 2021-10-11
 Source: Internet
 Author: User

Tags

new world history

drug interaction website

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On September 13, 2021, AbbVie and REGENXBIO announced a strategic cooperation agreement to jointly develop and commercialize RGX-314
.

RGX-314 is a potential one-time gene therapy for the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy (DR) and other chronic retinal diseases

Wet AMD is characterized by the formation of new, leaking blood vessels in the retina, leading to loss of vision
.

RGX-314 delivers transgenes to cells via the AAV8 vector

Diabetic retinopathy (DR) is the leading cause of vision loss in adults aged 24-75 years in the world
.

As DR progresses, a large proportion of patients develop vision-threatening complications, including diabetic macular edema (DME) and neovascularization that can lead to blindness

▲Introduction of RGX-314 (picture source: REGENXBIO official website)

REGENXBIO is advancing the study of RGX-314 through two different routes of administration to the eye
.

The therapy is currently in a pivotal trial of subretinal drug delivery to treat patients with wet AMD, and two phase 2 clinical trials of drug delivery via the internal suprachoroidal space to treat wet AMD and DR patients

In addition, AbbVie will pay REGENXBIO an upfront payment of US$370 million, and REGENXBIO may receive up to US$1.

Reference materials:

[1] AbbVie and REGENXBIO Announce Eye Care Collaboration.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.